Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy

A legfontosabb adatok

Ki végzi
Dr. Paul Lyons
Hol
Winchester (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2024. nov. 1.
Befejezés
2025. ápr. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • PO BRC-003 (High Cannabidiol Cannabis Extract)
  • Placebo
A regiszteradat frissítve
2025. április 24.
Miért állt le
Company decision

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must meet all of the following criteria to be eligible for enrollment into the study:
  • Diagnosis consistent with PTE,; and -
  • History of a trial of at least two AEDs, including one trial of a combination of two concomitant AEDs, without successful seizure control. Vagus nerve stimulation (VNS), RNS, deep brain stimulation (DBS), or the ketogenic diet can be considered an equivalent to a drug trial,
  • Between 1-4 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment,
  • VNS, DBS, or RNS must be on stable settings for a minimum of 3 months,
  • If on ketogenic diet, must be on stable ratio for a minimum of 3 months
  • If applicable, documentation (including date of surgery) of prior VNS, DBS, RNS, Corpus Callosotomy, or other epilepsy surgery the patient has received
  • Age 18 years and older
  • Acceptable method of contraception (or abstinence) for women of childbearing potential and for male patients with partners of childbearing potential; female patients must have a negative urine pregnancy test on the day of initiating IMP
  • Weight ≥ 40 kg

Ki nem vehet részt

  • Participants meeting any of the following criteria will not be eligible for participation in the study:; Active psychogenic non-epileptic seizures (PNES),; Patients who are pregnant, breastfeeding, or not using acceptable methods of contraception during the course of the study and for three months thereafter,; Male patient's partner is of childbearing potential; unless willing to ensure that they (male patients) or their partner(s) are using acceptable methods of contraception during the course of the study and for three months thereafter,; Use of medical marijuana, cannabis, hemp, or CBD based product in the previous 30 days, or during the study; Weight ≤ 40 kg; Initiation of felbamate within the last 12 months,; Allergy to CBD or any cannabis-type products,; ALT >5 × ULN or AST >5 × ULN, as seen in participant's laboratory results,; Hemoglobin <10 or hematocrit <30 or WBC < 2000, as seen in participant's laboratory results,; Current (as assessed via C-SSRS) or history of suicidal ideation or attempt,; In PI's judgment, active medical condition/treatment that impacts study activities,; Unable to provide consent,; No access to a mobile phone, and internet, not willing or able to download the eDiary application,; Inability or failure to comply with study visits, requirements and/or instructions, and; For Part B, prior enrollment in Part A of the study

Helyszínek itt: Egyesült Államok

  • Winchester Medical CenterWinchester, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This prospective double blind phase II study seeks to evaluate the safety and efficacy of BRC-003, a high CBD investigational product, in the treatment of refractory PTE (Post-Traumatic Epilepsy). The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B). This design aims to provide a thorough understanding of the investigational product's impact on seizure frequency, seizure severity, mood, anxiety, sleep, and quality of life.

A vizsgálat 2 csoportja

  • Part A and Part BA vizsgált kezelés

    Interventions: Drug: BRC-003 (High Cannabidiol Botanical Extract) 100 mg/mL

    Kezelés: PO BRC-003 (High Cannabidiol Cannabis Extract)

  • Part BPlacebo, összehasonlításként

    Placebo Comparator: 1 Placebo Half of the patients will receive PO placebo Interventions: Drug: Placebo

    Kezelés: Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized Controlled Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
A regiszteradat frissítve
2025. április 24.